omniture
logo
Search
GUARDANT HEALTH PTE LTD
Media Room

Latest News

rss

Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for amivantamab-vmjw to identify patients with inoperable or recurrent NSCLC harbouring EGFR exon 20 insertion mutations

* Guardant360® CDx is the first blood-based companion diagnostic to be approved inJapan for the d...

2024-08-30 11:01 3622

Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa

PALO ALTO, Calif., Jan. 8, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading preci...

2024-01-08 15:30 1546

Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea

SINGAPORE, Nov. 13, 2023 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision on...

2023-11-13 08:00 2823

Guardant Health Receives Regulatory Approval from Singapore's Health Sciences Authority for Guardant360® CDx blood test for patients with advanced solid cancers

* Guardant360® CDx is a comprehensive genomic profiling blood test that provides critical informa...

2023-05-30 09:00 2964

Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China

Collaboration will provide biopharmaceutical companies access to Guardant Health's broad portfolio ...

2022-07-06 18:17 3649

Guardant Health Receives Regulatory Approval for Guardant360 CDx in Japan

TOKYO, March 14, 2022 /PRNewswire/ -- The Ministry of Health, Labour and Welfare (MHLW) has granted...

2022-03-14 16:22 2337

Guardant360 CDx submitted for regulatory approval in Japan

TOKYO, Feb. 3, 2021 /PRNewswire/ -- Guardant Health Japan, an affiliate of Guardant Health Asia,Mid...

2021-02-03 18:41 2907

First liquid biopsy to receive FDA Approval for comprehensive tumor profiling across all solid cancers, Guardant Health's Guardant360® CDx, gains credibility among oncologists in Asia, Middle East and Africa.

SINGAPORE, Aug. 8, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved G...

2020-08-08 03:21 5797

Guardant360 test results may provide prognostic information beyond the detection of actionable biomarkers for ALK-rearranged NSCLC patients

SINGAPORE, May 30, 2020 /PRNewswire/ -- According to the data presented at the American Society of ...

2020-05-30 19:00 3416